Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $83.27
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jul 23, 21 | HSBC | upgrade | Hold | Buy |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 48.28 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 88.18 | Oscillator | Sell |
| Williams %R (14) | -24.16 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.43 (Hist 0.28) | Oscillator | Buy |
| Average Directional Index (14) | 17.61 (+DI 27.9 / -DI 34.3) | Trend | Neutral |
| EMA 20 | 83.40 | MA | Sell |
| SMA 20 | 82.86 | MA | Buy |
| EMA 50 | 83.84 | MA | Sell |
| SMA 50 | 85.03 | MA | Sell |
| SMA 200 | 78.67 | MA | Strong Buy |
Stock news · updated daily
ageas SA/NV (AGESY) Q2 2026 Earnings Call Transcript
ADTN, AGESY and EC have been added to the Zacks Rank #5 (Strong Sell) List on August 5th, 2026.
ageas SA/NV (AGESY) M&A Call Transcript
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 27, 2026 | 4.20 | 4.59 | Beat 9.3% | $3.22B |
| Feb 25, 2026 | 5.81 | 5.77 | Miss -0.7% | — |
| Aug 27, 2025 | 4.26 | 4.61 | Beat 8.2% | $2.60B |
| Feb 27, 2025 | 3.34 | 3.57 | Beat 6.9% | $2.17B |
| Feb 26, 2025 | 3.34 | 3.57 | Beat 6.9% | — |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | AGESY | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 7.6x | 7.8x · sector 20.4x | Discount |
| Forward P/E (FY26E) | 7.5x | EPS est. 11.10 | In line |
| Price / Book | 1.4x | 1.0x | Elevated |
| Price / Sales | 1.5x | 1.1x | Elevated |
| EV / EBITDA | 43.4x | 5.2x | Elevated |
| Return on equity | 19.1% | — | Healthy |
| Gross margin | 100.0% | 84.7% | Above hist. |
| Debt / Equity | 0.58 | 0.60 | Moderate |
| Piotroski / Altman Z | 5/9 | Z 0.13 | Distress |
Discounted cash flow model